Drug maker Lupin launches Mirabegron extended-release tablets in US market
The Mumbai-based drug maker Lupin has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.
Drug maker Lupin on Monday said it has launched Mirabegron extended-release tablets (25 mg) in the US market.
The Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic equivalent of Astellas Pharma Global Development, Inc's Myrbetriq extended-release tablets, it added.
Mirabegron extended-release tablets are used to treat certain bladder problems including overactive bladder.
Lupin shares were trading 3.38 per cent up at Rs 1,599.35 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.